<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25315">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02777203</url>
  </required_header>
  <id_info>
    <org_study_id>AHCIRB 6310 Power Morcellation</org_study_id>
    <nct_id>NCT02777203</nct_id>
  </id_info>
  <brief_title>Power Morcellation Systems for Laparoscopic Hysterectomy and Myomectomy</brief_title>
  <official_title>Safety and Efficacy of Contained Electromechanical Power Morcellation Systems for Laparoscopic Hysterectomy and Myomectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charles Miller</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Espiner Medical LTD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Advocate Health Care</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of insufflated bags for
      electromechanical power morcellation during laparoscopic hysterectomy and myomectomy for
      tissue removal and to observe the integrity of the bags throughout and after insufflation
      and power morcellation.

      The hypothesis is the bags will remain in tact without leakage from the bags during and
      after power morcellation using the described contained system, confirming the safety and
      efficacy of the systems.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Uterine leiomyoma (fibroids) are non-cancerous smooth muscle tumors that can cause heavy
      menstrual bleeding, pain, and pressure. Common surgical treatment modalities are
      hysterectomy (removal of the uterus) or myomectomy (removal of the fibroid). Minimally
      invasive surgical techniques (laparoscopy) are generally recommended due to improved
      recovery time, decrease infection risk, decreased bleeding risk and overall decreased
      morbidity and mortality risks.

      In order to remove a large uterus or large fibroids laparoscopically, a power morcellator is
      often used to cut the specimen into smaller pieces that can be removed through small
      incisions. Due to the concern regarding spread of small amounts of tissue during power
      morcellation, many surgeons are advocating contained power morcellation, i.e. morcellation
      inside a specimen bag.

      This study will be evaluating the efficacy of contained morcellation using two specific
      specimen bags. There will be two arms of the study, one utilizing each bag. Morcellation
      will be performed in the designated bag. The bag will then be removed evaluated for any egg
      albumin leakage. If there is no leakage, it can be inferred that there is no tissue is
      spread during the contained morcellation process using these bags.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Egg albumin leakage</measure>
    <time_frame>Day 0</time_frame>
    <description>Leakage of egg albumin from the EcoSac bags after isolated bag morcellation or apparent leakage of specimen from the EcoSac bags during isolated bag morcellation. After morcellation is complete, the bag will be removed from the patient and tested in a separate room. 100 milliliters of egg albumin combined with methylene blue will be placed into the bag and the bag will be insufflated. Visual inspection will be used to assess leakage from the bag with outcome measures of &quot;yes&quot; or &quot;no.&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morcellation time (group 1 and 2)</measure>
    <time_frame>Day 0</time_frame>
    <description>Time (in minutes) from insertion of the bag to removal of the bag</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GelPOINT placement time (group 1)</measure>
    <time_frame>Day 0</time_frame>
    <description>Time (in minutes) to place the GelPOINT Mini Advanced Access System</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Leiomyoma</condition>
  <arm_group>
    <arm_group_label>EcoSac 230 Arm - GROUP 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EcoSac 230 arm will have the GelPOINT Mini Advanced Access Platform placed at the beginning of their procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EcoSac 400 ECO-T Arm - GROUP 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EcoSac 400 ECO-T arm will undergo surgery in the standard multiport laparoscopic technique.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EcoSac 230</intervention_name>
    <description>The specimen will be morcellated in the EcoSac 230.</description>
    <arm_group_label>EcoSac 230 Arm - GROUP 1</arm_group_label>
    <other_name>EMP230ECO, Applied medical CNGL3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EcoSac 400 ECO-T</intervention_name>
    <description>Laparoscopy will be performed in the standard multi-port technique. The specimen will be morcellated in the EcoSac400 ECO-T bag.</description>
    <arm_group_label>EcoSac 400 ECO-T Arm - GROUP 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GelPOINT Mini Advanced Access Platform</intervention_name>
    <description>The GelPOINT Mini Advanced Access Platform will be placed at the beginning of the case.</description>
    <arm_group_label>EcoSac 230 Arm - GROUP 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult premenopausal women (equal or greater than 18 years old)

          -  no symptoms of menopause

          -  undergoing robotic or laparoscopic total or supracervical hysterectomies or
             myomectomies for the indication of symptomatic uterine fibroids

          -  not candidates for specimen removal via mini-laparotomy incision (as deemed by the
             study surgeon) or who have refused mini-laparotomy

          -  endometrial biopsy with no suspicion for malignancy

        Exclusion Criteria:

          -  known or suspected malignancy

          -  peri- or post-menopausal women

          -  specimen that can be removed without power morcellation (e.g., vaginally or through
             laparoscopic trocars)

          -  adults unable to consent.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Advocate Health Care</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mary Johnston, BSN</last_name>
    <phone>6303641112</phone>
    <email>mjohnston@charlesemillermd.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Advocate Lutheran General Hospital</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Miller, MD</last_name>
      <phone>630-428-2229</phone>
      <email>Chuckmillermd@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cholkeri-Singh A, Miller CE. Power morcellation in a specimen bag. J Minim Invasive Gynecol. 2015 Feb;22(2):160. doi: 10.1016/j.jmig.2014.10.012.</citation>
    <PMID>25460317</PMID>
  </reference>
  <reference>
    <citation>Cohen SL, Einarsson JI, Wang KC, Brown D, Boruta D, Scheib SA, Fader AN, Shibley T. Contained power morcellation within an insufflated isolation bag. Obstet Gynecol. 2014 Sep;124(3):491-7. doi: 10.1097/AOG.0000000000000421.</citation>
    <PMID>25162248</PMID>
  </reference>
  <reference>
    <citation>Einarsson JI, Cohen SL, Fuchs N, Wang KC. In-bag morcellation. J Minim Invasive Gynecol. 2014 Sep-Oct;21(5):951-3. doi: 10.1016/j.jmig.2014.04.010.</citation>
    <PMID>24769447</PMID>
  </reference>
  <reference>
    <citation>Kho KA, Anderson TL, Nezhat CH. Intracorporeal electromechanical tissue morcellation: a critical review and recommendations for clinical practice. Obstet Gynecol. 2014 Oct;124(4):787-93. doi: 10.1097/AOG.0000000000000448. Review.</citation>
    <PMID>25198260</PMID>
  </reference>
  <reference>
    <citation>Vargas MV, Cohen SL, Fuchs-Weizman N, Wang KC, Manoucheri E, Vitonis AF, Einarsson JI. Open power morcellation versus contained power morcellation within an insufflated isolation bag: comparison of perioperative outcomes. J Minim Invasive Gynecol. 2015 Mar-Apr;22(3):433-8. doi: 10.1016/j.jmig.2014.11.010.</citation>
    <PMID>25452122</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 17, 2017</lastchanged_date>
  <firstreceived_date>May 10, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Advocate Health Care</investigator_affiliation>
    <investigator_full_name>Charles Miller</investigator_full_name>
    <investigator_title>Obstetrician Gynecologist Surgeon</investigator_title>
  </responsible_party>
  <keyword>morcellation</keyword>
  <keyword>myomectomy</keyword>
  <keyword>hysterectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leiomyoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
